PPT-Measles and rubella investment cases: Stakeholder analysis

Dr Kimberly M Thompson 11 th Annual Measles and Rubella Partners Meeting September 19 2012 Acknowledgments World Health Organization WHO Contract PO 200470477 APW Radboud Duintjer . Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . 11. th. Annual Meeting . Measles and Rubella Initiative. Washington, DC. Peter Strebel, WHO/EPI. The mission of the Decade of Vaccines is to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live.". --Who We Are--. Stephen Cochi, . MD, MPH. Global . Immunization Division. Centers . for . Disease Control & Prevention. What is the Measles & Rubella Initiative? . Anne Ray Charitable Trust. Panel 01502. Vicki Stambos. The 13. th. Global Measles and Rubella Laboratory Network Meeting, Geneva, Switzerland, 29. th. June to 1. st. July 2015. Vicki Stambos. Accelerating Progress Towards Measles and Rubella Control and Elimination Meeting. 11. th. Annual Meeting . Measles and Rubella Initiative. Washington, DC. Peter Strebel, WHO/EPI. The mission of the Decade of Vaccines is to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live.". --Who We Are--. Stephen Cochi, . MD, MPH. Global . Immunization Division. Centers . for . Disease Control & Prevention. What is the Measles & Rubella Initiative? . Anne Ray Charitable Trust. Dr. Kimberly M. Thompson. Kid Risk, Inc., www.kidrisk.org. Topics. Context. I. ntegrated dynamic disease and economic . modeling. Discussion. http://www.wpro.who.int/vietnam/topics/immunization/measles_rubella/measles_rubella_big.png?ua=1. M&RI Partners’ Meeting. Michael F Thomas, . Director Vaccine Implementation. September 2017, Washington DC. Page: . 1. Reach every child. . Measles and Rubella support in Gavi countries by end of 2016. 2020. . Summary of the . Findings . and Implementation Status . Dr Kaushik . Banerjee. M&RI Partners' Meeting. Washington DC. 7 September 2017. 1. Objectives . of . the Review. To provide a candid review of progress . Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Dr. Kimberly M. Thompson. Kid Risk, Inc., www.kidrisk.org. Topics. Context. I. ntegrated dynamic disease and economic . modeling. Discussion. http://www.wpro.who.int/vietnam/topics/immunization/measles_rubella/measles_rubella_big.png?ua=1. ALL students are REQUIRED to provide proof of immunity to measles, mumps, and rubella (“MMR”). Before students may enroll in classes, NAU requires documentation of ONE of the following: • Tw Opening Comments & Perspectives. Dr. Suresh Jadhav. Executive Director. Serum Institute of India Pvt. Ltd.,. ssj@seruminstitute.com. . We, at Serum Institute of India Pvt. Ltd., feel proud of being a partner to PAHO / WHO in achieving what is designated to be a historical achievement in eradication of Measles & Rubella diseases from the Americas.. Source. : ISIS, MESS and country reports. | . *Data as of 1 May 2023.. N=. 18,897. 20,064. 18,971. 13,009. 13,308. 41,663. 91,950. 25,693. 9,318. 14,927. Text. In the last 10 years, there was a downward trend in the notification rate of suspected measles and rubella cases, reaching its lowest point in 2021: .